St. Jude studies have pioneered how the world treats childhood leukemia, helping to increase the cure rate. Scientists at St. Jude are leading studies to understand how to personalize treatments better by increasing therapy for those at high risk of relapse and reducing therapy to limit the late effects of care for those likely to be cured.
Leukemia Experts
-
Hiroto Inaba, MD, PhD
Inaba
Hiroto Inaba, MD, PhD, is director of the Pediatric Hematology-Oncology Fellowship Program. He leads clinical trials to improve the treatment of pediatric leukemia, finding ways to lower treatment intensity to minimize late effects of childhood cancer therapy.
-
Jeffery Klco, MD, PhD, St. Jude Department of Pathology, studies the genomics of pediatric myeloid tumors and myelodysplastic syndromes, working to understand the signaling pathways that contribute to myeloid cell development and these pathologies.
-
Charles Mullighan, MBBS, MSc, MD, St. Jude Department of Pathology, is deputy director of the St. Jude Comprehensive Cancer Center. His research uses integrated genomic and epigenomic approaches to understand acute lymphoblastic leukemia and related disorders.
-
Ching-Hon Pui, MD, St. Jude Global China Regional Program director, has helped change how acute lymphoblastic leukemia (ALL) is treated worldwide, improving survival rates while providing less toxic treatments. His partnerships in China have had a profound influence, helping convince the Chinese government in 2010 to extend health coverage to patients with childhood leukemia.
-
Jun J. Yang, PhD
Yang
Jun J. Yang, PhD, St. Jude Departments of Pharmacy & Pharmaceutical Sciences and Oncology, uses pharmacogenomics to identify new therapies for pediatric leukemia and understand treatment resistance. Yang leverages genetic insights to identify ways to improve leukemia therapy.
